{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:03:19Z","timestamp":1784178199647,"version":"3.55.0"},"reference-count":13,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Secondary hyperparathyroidism is a frequent component of chronic kidney disease-mineral and bone disorder in maintenance hemodialysis. Calcitriol and paricalcitol are used to suppress intact parathyroid hormone (iPTH), but the comparative advantage of paricalcitol in routine practice remains uncertain. This study compared 6-month biochemical PTH control in patients treated with intravenous calcitriol or intravenous paricalcitol. Methods: In this single-center retrospective cohort study, 312 adult hemodialysis patient files from 2023 to 2025 were screened. Patients who did not receive either intravenous study agent, switched between agents, or did not complete 6 months of treatment with the same agent were excluded. The final cohort included 185 patients, 100 treated with calcitriol and 85 with paricalcitol. The primary endpoint was target iPTH at 6 months, defined as 150\u2013600 pg\/mL. Results: Mean age was 58.9 \u00b1 13.6 years, and 106 patients were male. Baseline iPTH was similar in the calcitriol and paricalcitol groups (684 \u00b1 268 vs. 712 \u00b1 291 pg\/mL; p = 0.498). At 6 months, iPTH decreased significantly in both groups, with no significant between-group difference in follow-up iPTH (421 \u00b1 214 vs. 398 \u00b1 205 pg\/mL; p = 0.456), percentage iPTH reduction (\u221236.8 \u00b1 22.4% vs. \u221239.5 \u00b1 24.1%; p = 0.431), or target iPTH achievement (62.0% vs. 60.0%; p = 0.781). Hypercalcemia and hyperphosphatemia rates were also similar. In multivariable analysis, treatment type was not independently associated with target iPTH achievement, whereas higher baseline iPTH and phosphorus were associated with lower odds of achieving target iPTH. Conclusions: Intravenous paricalcitol was not associated with superior 6-month PTH control compared with intravenous calcitriol in this real-world maintenance hemodialysis cohort. The findings indicate no demonstrated superiority of paricalcitol in this cohort and should not be interpreted as proof of pharmacological equivalence.<\/jats:p>","DOI":"10.3390\/jcm15145483","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:34:44Z","timestamp":1783996484000},"page":"5483","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravenous Paricalcitol Versus Calcitriol for Secondary Hyperparathyroidism in Maintenance Hemodialysis: A Six-Month Single-Center Retrospective Cohort Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9504-8263","authenticated-orcid":false,"given":"Erman","family":"\u00d6zdemir","sequence":"first","affiliation":[{"name":"Department of Nephrology, Pendik State Hospital, 34890 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8901-952X","authenticated-orcid":false,"given":"Erdo\u011fan","family":"\u00d6zdemir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Elaz\u0131\u011f Fethi Sekin City Hospital, 23100 Elaz\u0131\u011f, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8456-713X","authenticated-orcid":false,"given":"P\u0131nar","family":"\u00d6zdemir","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, 34865 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(2017). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 7, 1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Jean, G., Souberbielle, J.C., and Chazot, C. (2017). Vitamin D in Chronic Kidney Disease and Dialysis Patients. Nutrients, 9.","DOI":"10.3390\/nu9040328"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus Calcitriol in the Treatment of Secondary Hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hansen, D., Brandi, L., and Rasmussen, K. (2009). Treatment of Secondary Hyperparathyroidism in Haemodialysis Patients: A Randomised Clinical Trial Comparing Paricalcitol and Alfacalcidol. BMC Nephrol., 10.","DOI":"10.1186\/1471-2369-10-28"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/nep.12029","article-title":"Randomized Controlled Trial to Compare the Efficacy and Safety of Oral Paricalcitol with Oral Calcitriol in Dialysis Patients with Secondary Hyperparathyroidism","volume":"18","author":"Ong","year":"2013","journal-title":"Nephrology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/1744-9987.12760","article-title":"Comparison of Paricalcitol and Calcitriol in Dialysis Patients with Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies","volume":"23","author":"Zhang","year":"2019","journal-title":"Ther. Apher. Dial."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Xie, Y., Su, P., Sun, Y., Zhang, H., Zhao, R., Li, L., and Meng, L. (2017). Comparative Efficacy and Safety of Paricalcitol versus Vitamin D Receptor Activators for Dialysis Patients with Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Trials. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0691-6"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Geng, X., Shi, E., Wang, S., and Song, Y. (2020). A Comparative Analysis of the Efficacy and Safety of Paricalcitol versus Other Vitamin D Receptor Activators in Patients Undergoing Hemodialysis: A Systematic Review and Meta-Analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0233705"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"110817","DOI":"10.5527\/wjn.v14.i4.110817","article-title":"Comparison of Parathormone Lowering Effects of Paricalcitol and Calcitriol in Hemodialysis Patients","volume":"14","author":"Murt","year":"2025","journal-title":"World J. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","article-title":"Paricalcitol-Treated Patients Experience Improved Hospitalization Outcomes Compared with Calcitriol-Treated Patients in Real-World Clinical Settings","volume":"19","author":"Dobrez","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/0886022X.2011.647298","article-title":"Efficacy and Tolerability of Intravenous Paricalcitol in Calcitriol-Resistant Hemodialysis Patients with Secondary Hyperparathyroidism: 12-Month Prospective Study","volume":"34","author":"Tonbul","year":"2012","journal-title":"Ren. Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.10661013","article-title":"A Randomized Multicenter Trial of Paricalcitol versus Calcitriol for Secondary Hyperparathyroidism in Stages 3-4 CKD","volume":"9","author":"Coyne","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5483\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:11:19Z","timestamp":1784175079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":13,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145483"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145483","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]}}}